4.6 Article

STAT3 but Not HIF-1 Is Important in Mediating Hypoxia-Induced Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line

Journal

CANCERS
Volume 9, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/cancers9100137

Keywords

hypoxia-induced chemoresistance; HIF-1; STAT3; cisplatin; cancer stemness

Categories

Funding

  1. Canadian Institutes of Health Research (CIHR)
  2. Canadian Breast Cancer Foundation (CBCF)
  3. Women and Children's Health Research Institute (WCHRI)
  4. Alberta Cancer Foundation (ACF)
  5. CBCF

Ask authors/readers for more resources

Hypoxia-induced chemoresistance (HICR) is a well-recognized phenomenon, and in many experimental models, hypoxia inducible factor-1 (HIF-1) is believed to be a key player. We aimed to better understand the mechanism underlying HICR in a triple negative breast cancer cell line, MDA-MB-231, with a focus on the role of HIF-1. In this context, the effect of hypoxia on the sensitivity of MDA-MB-231 cells to cisplatin and their stem-like features was evaluated and the role of HIF-1 in both phenomena was assessed. Our results showed that hypoxia significantly increased MDA-MB-231 resistance to cisplatin. Correlating with this, intracellular uptake of cisplatin was significantly reduced under hypoxia. Furthermore, the stem-like features of MDA-MB-231 cells increased as evidenced by the significant increases in the expression of ATP-binding cassette (ABC) drug transporters, the proportion of CD44(+)/CD24(-) cells, clonogenic survival and cisplatin chemoresistance. Under hypoxia, both the protein level and DNA binding of HIF-1 was dramatically increased. Surprisingly, siRNA knockdown of HIF-1 did not result in an appreciable change to HICR. Instead, signal transducer and activator of transcription 3 (STAT3) activation was found to be important. STAT3 activation may confer HICR by upregulating ABC transporters, particularly ABCC2 and ABCC6. This study has demonstrated that, in MDA-MB-231 cells, STAT3 rather than HIF-1 is important in mediating HICR to cisplatin.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available